Aarti Drugs Limited
Aarti Drugs Limited (AARTIDRUGS.NS) Stock Technical Analysis & Trading Signals
Live technical indicators, trading signals, and momentum insights for Aarti Drugs Limited (NSE:AARTIDRUGS.NS).
Disclaimer for Technical Analysis Page
The technical indicators and trading signals shown on this page are for informational purposes only and do not constitute financial advice. Stock market investments involve risk, and past performance is not a guarantee of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.Read our Full DisclaimerAARTIDRUGS.NS Technical Analysis Summary
Aarti Drugs Limited stock currently shows a bullish trend, supported by momentum and strong buying pressure.
This mix signals that Aarti Drugs Limited is trading in a balanced range with no clear breakout yet.
RSI (14): 67.12
Stochastic %K: 81.40
Williams %R: -5.68
Rate of Change (ROC): 11.48
Takeaway:Aarti Drugs Limited shows strong bullish momentum, with buyers firmly in control.
MACD: 7.88
ADX: 23.98
ATR (14): 12.89
CCI (14): 190.57
Takeaway:Aarti Drugs Limited shows a firm trend supported by momentum, though one signal suggests caution.
Takeaway:Aarti Drugs Limited trades near the upper band, signaling overbought conditions and risk of pullback.
Takeaway:Aarti Drugs Limited trades above the trend line, showing healthy momentum within the channel.
Overall Takeaway:AARTIDRUGS.NS shows bullish money flow, with volume and vigor supporting buyers.
Bullish Signals
RSI above 50 → positive momentum from buyers.
MACD above 0 → bullish trend confirmation.
ADX above 20 → strong underlying trend.
Price trading above middle Bollinger Band → mid-term support intact.
MFI below 80 → room for more buying without overbought risk.
Bearish Signals
Price near upper Bollinger Band → potential resistance and pullback risk.
Overall Recommendation:Aarti Drugs Limited currently shows a Buy with caution signal — momentum and trend strength are positive, but price is close to resistance and may face short-term pullbacks.